However, the current status of clinical trials on anti-PD-1/PD-L1 for nasopharyngeal carcinoma remains unclear. Therefore, this study aims to provide a comprehensive analysis of the registered trials related to anti-PD-1/PD-L1 for nasopharyngeal carcinoma on ClinicalTrials.gov. M...
看到在clinical trials网站上,BMS登记了一项三期临床试验NCT06561386,Anti-PD-1抗体Nivolumab(O药)+Anti-LAG-3抗体Relatlimab联合化疗, 在PD-L1表达量为1-49%的非鳞状晚期非小细胞肺癌的一线治疗中,默沙东Anti-PD-1抗体Pembrolizumab(K药)联合化疗的,头对头比对三期临床试验,这一临床试验虽不敢说是标志性事件,但是...
含有anti-PD-(L)1单臂的双抗可以看作是anti-PD-(L)1联合用药的一种特殊格式。现在让我们来看一下不含anti-PD-(L)1单臂的双抗与anti-PD-(L)1组合的情况。如果说anti-PD-(L)1单抗的作用是“松开刹车”的主要方式,那桥接CD3和肿瘤关联抗原(TAA...
Our study suggests that the combination of a PD-1 antibody, an HDACi, and a VEGF antibody could be a promising treatment regimen for patients with MSS/pMMR advanced colorectal cancer. ClinicalTrials.gov registration: NCT04724239.This is a preview of subscription content, access via your ...
更进一步,Roche和合作方Incyte决定关闭IDO抑制剂(Epacadostat)联合PD-L1抑制剂(Atezolizumab临床试验 ECHO-110的患者招募,官方给出的理由是招募进度缓慢。下图是clinicaltrials上显示的该临床项目状态: ECHO-110临床状态 在2017年召开的ASCO年会上, Incyte公布Epacadostat (IDO抑制剂)联合 Keytruda (pembrolizumab)治疗三...
The potential pitfalls and precautions, based on clinical experience from treating patients with cancer with PD-1/PD-L1 pathway inhibitors, are also described. Conclusions Anti-PD-1/PD-L1 therapy holds promise as adjunctive therapy for chronic infectious diseases such as tuberculosis and HIV, and ...
Clinical studies of the combination of anti-PD-1 and targeted therapy in GC & CRC Clinical trials have explored multiple combinatorial regimens based on concrete evidence that combining targeted therapy and anti-PD-1 agents is feasible. Until now, studies have mainly focused on those therapies that...
Anti-PD-1 clone NAT105 DIA-PD1说明书 Version:Page:2 1 of 3
Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not candidates for ...
Fourth, at present, the sizes of clinical cohorts treated with anti-PD-1 therapy are still very limited, making genetic association analyses of response to anti-PD-1 statistically underpowered6. Some large-scale cancer genome projects, such as TCGA, have revealed the genomic landscapes of many ...